Article: FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer
| Title | FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Authors | Karadedou, CT3 Gomes, AR3 Chen, J2 3 Petkovic, M3 Ho, KK3 Zwolinska, AK3 Feltes, A3 Wong, SY2 Chan, KYK2 Cheung, YN2 Tsang, JWH1 Brosens, JJ3 Khoo, US2 Lam, EWF3 | ||||||||
| Issue Date | 2012 | ||||||||
| Publisher | Nature Publishing Group. The Journal's web site is located at http://www.nature.com/onc | ||||||||
| Citation | Oncogene, 2012, v. 31 n. 14, p. 1845-1858 [How to Cite?] DOI: http://dx.doi.org/10.1038/onc.2011.368 | ||||||||
| Abstract | Vascular endothelial growth factor (VEGF) has a central role in breast cancer development and progression, but the mechanisms that control its expression are poorly understood. Breast cancer tissue microarrays revealed an inverse correlation between the Forkhead transcription factor Forkhead box class O (FOXO)3a and VEGF expression. Using the lapatinib-sensitive breast cancer cell lines BT474 and SKBR3 as model systems, we tested the possibility that VEGF expression is negatively regulated by FOXO3a. Lapatinib treatment of BT474 or SKBR3 cells resulted in nuclear translocation and activation of FOXO3a, followed by a reduction in VEGF expression. Transient transfection and inducible expression experiments showed that FOXO3a represses the proximal VEGF promoter, whereas another Forkhead member, FOXM1, induces VEGF expression. Chromatin immunoprecipitation and oligonucleotide pull-down assays showed that both FOXO3a and FOXM1 bind a consensus Forkhead response element (FHRE) in the VEGF promoter. Upon lapatinib stimulation, activated FOXO3a displaces FOXM1 bound to the FHRE before recruiting histone deacetylase 2 (HDAC2) to the promoter, leading to decreased histones H3 and H4 acetylation, and concomitant transcriptional inhibition of VEGF. These results show that FOXO3a-dependent repression of target genes in breast cancer cells, such as VEGF, involves competitive displacement of DNA-bound FOXM1 and active recruitment of transcriptional repressor complexes. | ||||||||
| ISSN | 0950-9232 2011 Impact Factor: 6.373 2011 SCImago Journal Rankings: 1.216 | ||||||||
| DOI | http://dx.doi.org/10.1038/onc.2011.368 | ||||||||
| ISI Accession Number ID | WOS:000302785200010
Funding Information: This study was supported by the Cancer Research UK (M Petkovic, KK Ho and EW-F Lam), Breast Cancer Campaign (EW-F Lam), the Portuguese Science and Technology Foundation (FCT; AR Gomes). | ||||||||
| PubMed Central ID | PMC3232453 | ||||||||
| References | References in Scopus |
| dc.contributor.author | Karadedou, CT | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| dc.contributor.author | Gomes, AR | ||||||||
| dc.contributor.author | Chen, J | ||||||||
| dc.contributor.author | Petkovic, M | ||||||||
| dc.contributor.author | Ho, KK | ||||||||
| dc.contributor.author | Zwolinska, AK | ||||||||
| dc.contributor.author | Feltes, A | ||||||||
| dc.contributor.author | Wong, SY | ||||||||
| dc.contributor.author | Chan, KYK | ||||||||
| dc.contributor.author | Cheung, YN | ||||||||
| dc.contributor.author | Tsang, JWH | ||||||||
| dc.contributor.author | Brosens, JJ | ||||||||
| dc.contributor.author | Khoo, US | ||||||||
| dc.contributor.author | Lam, EWF | ||||||||
| dc.date.accessioned | 2012-05-29T06:14:43Z | ||||||||
| dc.date.available | 2012-05-29T06:14:43Z | ||||||||
| dc.date.issued | 2012 | ||||||||
| dc.description.abstract | Vascular endothelial growth factor (VEGF) has a central role in breast cancer development and progression, but the mechanisms that control its expression are poorly understood. Breast cancer tissue microarrays revealed an inverse correlation between the Forkhead transcription factor Forkhead box class O (FOXO)3a and VEGF expression. Using the lapatinib-sensitive breast cancer cell lines BT474 and SKBR3 as model systems, we tested the possibility that VEGF expression is negatively regulated by FOXO3a. Lapatinib treatment of BT474 or SKBR3 cells resulted in nuclear translocation and activation of FOXO3a, followed by a reduction in VEGF expression. Transient transfection and inducible expression experiments showed that FOXO3a represses the proximal VEGF promoter, whereas another Forkhead member, FOXM1, induces VEGF expression. Chromatin immunoprecipitation and oligonucleotide pull-down assays showed that both FOXO3a and FOXM1 bind a consensus Forkhead response element (FHRE) in the VEGF promoter. Upon lapatinib stimulation, activated FOXO3a displaces FOXM1 bound to the FHRE before recruiting histone deacetylase 2 (HDAC2) to the promoter, leading to decreased histones H3 and H4 acetylation, and concomitant transcriptional inhibition of VEGF. These results show that FOXO3a-dependent repression of target genes in breast cancer cells, such as VEGF, involves competitive displacement of DNA-bound FOXM1 and active recruitment of transcriptional repressor complexes. | ||||||||
| dc.description.nature | link_to_OA_fulltext | ||||||||
| dc.identifier.citation | Oncogene, 2012, v. 31 n. 14, p. 1845-1858 [How to Cite?] DOI: http://dx.doi.org/10.1038/onc.2011.368 | ||||||||
| dc.identifier.citeulike | 9804826 | ||||||||
| dc.identifier.doi | http://dx.doi.org/10.1038/onc.2011.368 | ||||||||
| dc.identifier.epage | 1858 | ||||||||
| dc.identifier.hkuros | 206644 | ||||||||
| dc.identifier.isi | WOS:000302785200010
Funding Information: This study was supported by the Cancer Research UK (M Petkovic, KK Ho and EW-F Lam), Breast Cancer Campaign (EW-F Lam), the Portuguese Science and Technology Foundation (FCT; AR Gomes). | ||||||||
| dc.identifier.issn | 0950-9232 2011 Impact Factor: 6.373 2011 SCImago Journal Rankings: 1.216 | ||||||||
| dc.identifier.issue | 14 | ||||||||
| dc.identifier.pmcid | PMC3232453 | ||||||||
| dc.identifier.pmid | 21860419 | ||||||||
| dc.identifier.scopus | eid_2-s2.0-84860395525 | ||||||||
| dc.identifier.spage | 1845 | ||||||||
| dc.identifier.uri | http://hdl.handle.net/10722/148691 | ||||||||
| dc.identifier.volume | 31 | ||||||||
| dc.language | eng | ||||||||
| dc.publisher | Nature Publishing Group. The Journal's web site is located at http://www.nature.com/onc | ||||||||
| dc.publisher.place | United Kingdom | ||||||||
| dc.relation.ispartof | Oncogene | ||||||||
| dc.relation.references | References in Scopus | ||||||||
| dc.subject.mesh | Breast Neoplasms - metabolism | ||||||||
| dc.subject.mesh | Cell Line, Tumor | ||||||||
| dc.subject.mesh | Forkhead Transcription Factors - metabolism | ||||||||
| dc.subject.mesh | Gene Expression Regulation, Neoplastic | ||||||||
| dc.subject.mesh | Vascular Endothelial Growth Factor A - metabolism | ||||||||
| dc.title | FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer | ||||||||
| dc.type | Article |
Author Affiliations
- The University of Hong Kong Li Ka Shing Faculty of Medicine
- The University of Hong Kong
- Imperial College London

